according to Vertex. The FDA has prioritized the development of non-opioid alternatives, issuing guidelines and awarding grants to encourage safer pain treatments. "Today's approval is an important ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...